Bristol-Myers Squibb Company (BMY)
Automate Your Wheel Strategy on BMY
With Tiblio's Option Bot, you can configure your own wheel strategy including BMY - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock?
Published: March 02, 2026 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers rides growth brands like Opdivo and Reblozyl to offset generics, with pipeline catalysts and cost cuts shaping its next phase.
Read More
Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Published: March 02, 2026 by: Seeking Alpha
Sentiment: Neutral
Bristol-Myers Squibb Company (BMY) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Read More
Bristol Myers Squibb (BMY) is a Top-Ranked Momentum Stock: Should You Buy?
Published: February 26, 2026 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
Published: February 25, 2026 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
5 Very Safe High-Yield Dividend Stocks Boomers Can Hold Forever
Published: February 25, 2026 by: 24/7 Wall Street
Sentiment: Positive
While many Baby Boomers have enjoyed a long bull market over the past 35 years, there is a point when income becomes more critical than stock appreciation.
Read More
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Published: February 24, 2026 by: Zacks Investment Research
Sentiment: Positive
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read More
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
Published: February 23, 2026 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #BMS--Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia.
Read More
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
Published: February 20, 2026 by: Zacks Investment Research
Sentiment: Negative
BMY edges past MRK as generic headwinds bite, but new drug launches, cost cuts and a stronger 2026 outlook tilt the investment case in its favor.
Read More
Bristol-Myers Squibb: Oncology Franchise Remains A Core Strength
Published: February 19, 2026 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb Company ended 2025 and started this year on a high note. On February 6, its stock reached a 52-week high of $63.3. One of the reasons BMY is once again becoming a Wall Street favorite is the 49% year-over-year increase in Breyanzi sales to $392 million in Q4.
Read More
FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma
Published: February 18, 2026 by: Zacks Investment Research
Sentiment: Positive
FDA accepts and grants priority review to Bristol Myers' NDA for iberdomide combo in relapsed or refractory multiple myeloma. A decision is due on Aug. 17, 2026.
Read More
Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?
Published: February 17, 2026 by: Zacks Investment Research
Sentiment: Negative
BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.
Read More
Bristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on It
Published: February 11, 2026 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Will BMY's Legacy Portfolio Decline Weigh on Its 2026 Top Line?
Published: February 10, 2026 by: Zacks Investment Research
Sentiment: Negative
BMY's legacy drugs see sharp generic erosion in 2026, but Eliquis growth and guidance shape expectations as competition heats up in oncology.
Read More
BMY Up 7.6% Post Q4 Earnings: Should You Buy, Sell or Hold the Stock?
Published: February 09, 2026 by: Zacks Investment Research
Sentiment: Neutral
BMY jumps after strong Q4 2025 results as its growth portfolio drives beats, lifts sentiment and offsets generic pressure on legacy drugs.
Read More
Dow Tumbles Over 400 Points; Bristol Myers Reports Strong Q4 Results
Published: February 05, 2026 by: Benzinga
Sentiment: Neutral
U.S. stocks traded lower midway through trading, with the Dow Jones index falling more than 400 points on Thursday.
Read More
Weekly Jobless Claims Exceed Expectations
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Weekly Jobless Claims Exceed Expectations.
Read More
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY beats Q4 earnings and revenue estimates as its Growth Portfolio jumps 16%, lifting shares despite continued declines in legacy drugs.
Read More
Jobless Claims Pop Up a Bit, Major Morning for Earnings
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Jobless Claims notched their highest weekly print since early December, while BMY, RL, COP & more report earnings.
Read More
Bristol Myers Just Crushed Earnings, and the Real Catalyst Hasn't Even Hit Yet
Published: February 05, 2026 by: 24/7 Wall Street
Sentiment: Positive
Bristol Myers Squibb (NYSE:BMY) reported Q4 2025 revenue of $12.5 billion, essentially flat year-over-year, with full-year 2025 revenue reaching $48.2 billion.
Read More
Bristol Myers (BMY) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Although the revenue and EPS for Bristol Myers (BMY) give a sense of how its business performed in the quarter ended December 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Read More
Bristol Myers Squibb (BMY) Tops Q4 Earnings and Revenue Estimates
Published: February 05, 2026 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.26 per share, beating the Zacks Consensus Estimate of $1.15 per share. This compares to earnings of $1.67 per share a year ago.
Read More
Will Reblozyl Shine in Bristol Myers' Fourth-Quarter Results?
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY leans on fast-growing Reblozyl, now a $2B+ franchise, to fuel results as generics pressure legacy drugs ahead of Q4 earnings.
Read More
Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.
Published: February 03, 2026 by: Business Wire
Sentiment: Neutral
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #FXIa--Bristol Myers Squibb Introduces "Change the Target. Change What's Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, NVO, BMY and PFE prepare to reveal their Q4 results amid a strong sector start.
Read More
Unveiling Bristol Myers (BMY) Q4 Outlook: Wall Street Estimates for Key Metrics
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Neutral
Evaluate the expected performance of Bristol Myers (BMY) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Read More
Should You Buy, Hold, or Sell BMY Stock Ahead of Q4 Earnings?
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY heads into Q4 2025 earnings with strong Opdivo momentum, even as generic pressure continues to weigh on legacy drug sales.
Read More
Will BMY's Oncology Collaborations Drive Its Next Growth Phase?
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
BMY boosts its oncology pipeline with a Janux deal on tumor-activated therapy, alongside encouraging pumitamig data and multiple cancer collaborations.
Read More
Analysts Estimate Bristol Myers Squibb (BMY) to Report a Decline in Earnings: What to Look Out for
Published: January 29, 2026 by: Zacks Investment Research
Sentiment: Negative
Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Bristol-Myers Squibb: Solid Tumor Collaboration With Janux And Camzyos Expansion
Published: January 23, 2026 by: Seeking Alpha
Sentiment: Positive
Bristol-Myers Squibb (BMY) remains a Strong Buy as it accelerates Growth Portfolio revenues and executes strategic oncology expansion. BMY's collaboration with Janux Therapeutics positions it to enter the solid tumor market, leveraging TRACTr technology for long-term oncology growth. Camzyos delivered 89% YoY revenue growth and promising phase 3 SCOUT-HCM results, supporting potential label expansion to adolescent oHCM patients.
Read More
About Bristol-Myers Squibb Company (BMY)
- IPO Date 1972-06-01
- Website https://www.bms.com
- Industry Drug Manufacturers - General
- CEO Christopher S. Boerner
- Employees 34100